22 results
8-K
EX-99.1
TRML
Tourmaline Bio Inc
24 Jan 24
Results of Operations and Financial Condition
5:10pm
to their respective targets can result in inflammation, receptor activation, and further immune system attack. In some diseases, autoantibodies directed against cell … , the FDA approved the first targeted therapy for the treatment of TED: TEPEZZA® (teprotumumab), a monoclonal antibody that targets IGF-1R. In two
8-K
EX-10.7
TRML
Tourmaline Bio Inc
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
; pre-tax profit; operating cash flow; sales or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement
424B3
evur 9yaj
15 Sep 23
Prospectus supplement
6:31am
S-4/A
rniv0s ln2u
25 Aug 23
Registration of securities issued in business combination transactions (amended)
4:34pm
S-4
k1mj6hrrje06usvj
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
425
si3eglav bh5i
22 Jun 23
Business combination disclosure
9:12am
8-K
EX-2.1
75zox0ev
22 Jun 23
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
9:10am
DEF 14A
1o5u659
29 Apr 22
Definitive proxy
4:24pm
10-K
l9mceptj6
17 Mar 22
Annual report
4:31pm
424B4
qdip7lgnh4z ja
10 May 21
Prospectus supplement with pricing info
4:20pm
S-1/A
z2umyptsgok 5uvojd
3 May 21
IPO registration (amended)
6:07am
S-1
EX-10.5
rxms8l9uol
16 Apr 21
IPO registration
5:03pm
S-1
EX-10.1
dc9nmzq4ed4 hmy9
16 Apr 21
IPO registration
5:03pm